Pharming Group Elevates Status with Euronext AMX Index Inclusion

Leiden, September 10, 2025 — Global biopharmaceutical company Pharming Group N.V. has successfully advanced from the Euronext AScX® (Small Cap) segment to the AMX® (MidCap) index, a promotion set to take effect on September 22, 2025. The move comes following Euronext Amsterdam’s latest index review, which evaluated companies based on free-float market capitalization and trading liquidity. The AMX index currently comprises 25 mid-cap companies, and Pharming’s entry marks a significant milestone in the company’s market trajectory.

This elevation represents Pharming’s comeback to the AMX segment and underscores the company’s accelerating commercial execution and robust pipeline development. The index change is expected to enhance the company’s profile among institutional investors and broaden its market visibility.

Strategic Growth and Pipeline Momentum

Pharming, headquartered in Leiden, Netherlands, has established itself as a dedicated player in the rare disease space. The company’s portfolio spans both small molecule and biologic innovations aimed at addressing rare, debilitating, and life-threatening conditions. With operations spanning over 30 markets across North America, Europe, the Middle East, Africa, and Asia-Pacific, Pharming maintains a global footprint supported by employees dedicated to patient care.

CEO Fabrice Chouraqui highlighted the significance of the promotion: “This elevation to the AMX index reflects our financial strength and the momentum we’ve built in our pipeline development. The increased investor attention will complement our strategic focus on executing critical commercial milestones and advancing our rare disease portfolio toward becoming a global leader in this therapeutic space.”

The index promotion is expected to drive greater institutional participation and improve liquidity in Pharming’s shares, aligning with the company’s growth ambitions as it continues progressing its clinical and commercial initiatives.

About Pharming Group N.V.

Pharming Group N.V. (EURONEXT Amsterdam: PHARM / Nasdaq: PHAR) is a global biopharmaceutical company transforming patient outcomes in rare disease treatment. The company develops and commercializes a diverse pipeline of innovative therapeutics, incorporating both small molecules and biologics. Based in Leiden, Netherlands, with a global workforce, Pharming serves patients across multiple continents and therapeutic areas.

Media Contacts:

Pharming Group — Michael Levitan, VP Investor Relations & Corporate Communications | +1 (908) 705-1696

Corporate Communications — Saskia Mehring | +31 6 28 32 60 41

Investor Relations: investor@pharming.com

FTI Consulting (UK) — Simon Conway / Alex Shaw / Amy Byrne | +44 203 727 1000

LifeSpring Life Sciences Communication (Amsterdam) — Leon Melens | +31 6 53 81 64 27

US PR — Ethan Metelenis | +1 (917) 882-9038